Trilogy International Partners Inc., together with its subsidiaries, provides wireless voice and data communications services to customers and international visitors roaming on its networks in the United States, Bolivia, and New Zealand. Its wireless voice and data communications services include local, international long distance, and roaming services. The Company also provides fixed broadband communications services to business and residential customers. It serves approximately 15.4 million customers. The company is headquartered in Bellevue, Washington.
Industry, Sector and Symbol
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
Phone+1-425-4585900
Debt
Current Ratio0.89
Quick Ratio0.65
Price-To-Earnings
Sales & Book Value
Annual SalesC$791.59 million
Price / Sales0.12
Price / Cash Flow2.33
Price / Book-1.34
Profitability
Net IncomeN/A
Net MarginsN/A
Return on AssetsN/A
Miscellaneous
Employees1,883
OptionableNot Optionable
Trilogy International Partners (TSE:TRL) Frequently Asked Questions
What is Trilogy International Partners' stock symbol?
Trilogy International Partners trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TRL."
How often does Trilogy International Partners pay dividends? What is the dividend yield for Trilogy International Partners?
Trilogy International Partners declared a quarterly dividend on Friday, April 13th. Stockholders of record on Friday, May 4th will be given a dividend of 0.02 per share on Friday, May 4th. This represents a $0.08 annualized dividend and a dividend yield of 4.85%. The ex-dividend date is Friday, April 13th. View Trilogy International Partners' Dividend History.
How were Trilogy International Partners' earnings last quarter?
Trilogy International Partners Inc (TSE:TRL) posted its earnings results on Wednesday, November, 7th. The specialty pharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter. The specialty pharmaceutical company earned $248.84 million during the quarter. View Trilogy International Partners' Earnings History.
When is Trilogy International Partners' next earnings date?
What price target have analysts set for TRL?
3 analysts have issued 12-month price objectives for Trilogy International Partners' shares. Their predictions range from C$3.00 to C$8.00. On average, they anticipate Trilogy International Partners' share price to reach C$4.67 in the next twelve months. This suggests a possible upside of 182.8% from the stock's current price. View Analyst Price Targets for Trilogy International Partners.
What is the consensus analysts' recommendation for Trilogy International Partners?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trilogy International Partners in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Trilogy International Partners.
Has Trilogy International Partners been receiving favorable news coverage?
Media coverage about TRL stock has trended positive recently, InfoTrie reports. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Trilogy International Partners earned a daily sentiment score of 2.3 on InfoTrie's scale. They also gave press coverage about the specialty pharmaceutical company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the near term.
Who are some of Trilogy International Partners' key competitors?
Some companies that are related to Trilogy International Partners include Allergy Therapeutics (AGY), Antisense Therapeutics (ANP), AstraZeneca (AZN), Avivagen (VIV), Bayer (BAYN), Bayer (BAYN), BEXIMCO PHARMAC/S GDR REGS (BXP), Cathay International (CTI), China Pharma (CPHI), Dechra Pharmaceuticals (DPH), Eco Animal Health Group (EAH), Futura Medical (FUM), GlaxoSmithKline (GSK), Hutchison China MediTech (HCM) and Mayne Pharma Group (MYX).
Who are Trilogy International Partners' key executives?
Trilogy International Partners' management team includes the folowing people:
- Mr. John William Stanton, Co-Founder, Chairman & Lead Director (Age 63)
- Mr. Bradley Jay Horwitz, Co-Founder, Pres, CEO & Non-Independent Director (Age 62)
- Ms. Theresa E. Gillespie, Co-Founder & Non-Independent Director (Age 65)
- Mr. Erik Mickels, Sr. VP & CFO
- Mr. Scott Morris, Sr. VP, Gen. Counsel & Corp. Sec.
How do I buy shares of Trilogy International Partners?
Shares of TRL and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Trilogy International Partners' stock price today?
One share of TRL stock can currently be purchased for approximately C$1.65.
What is Trilogy International Partners' official website?
How can I contact Trilogy International Partners?
Trilogy International Partners' mailing address is Bellevue Wa PO Box 1988, BELLEVUE, WA 98009-1988, United States. The specialty pharmaceutical company can be reached via phone at +1-425-4585900.
MarketBeat Community Rating for Trilogy International Partners (TSE TRL)
MarketBeat's community ratings are surveys of what our community members think about Trilogy International Partners and other stocks. Vote "Outperform" if you believe TRL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRL will underperform the S&P 500 over the long term. You may vote once every thirty days.
